Ionis Announces Positive Results from Halos Phase 1/2a

Exciting news for the Angelman syndrome community! Ionis’ Angelman syndrome program, ION582, has just shared positive preliminary results from the Phase 1/2a HALOS clinical trial.  Ionis will be providing an update at the upcoming Angelman Syndrome Foundation meeting in July.

Read the community letter

See the full press release